Yukio Ozaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yukio Ozaki has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
- Yutaka Yatomi
Department of Clinical Laboratory Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo, 113-0033, JAPAN
12 shared publications S Kume
7 shared publicationsK. Satoh
5 shared publicationsK Satoh
4 shared publicationsK. Suzuki‐Inoue
University of Yamanashi Department of Laboratory Medicine, Faculty of Medicine Yamanashi Japan
3 shared publicationsKaneo Satoh
Department of Laboratory Medicine, School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
3 shared publications
Latest Publications
- Open Access
- 12 December 2018
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 16 (1) , 1-14
Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation
Previously, several studies have shown that Tyro3, Axl, and Mertk (TAM) receptors participate in platelet activation and thrombosis. However, the role of individual receptors is not fully understood. Using single receptor-deficient platelets from TAM knockout mice in the C57BL/6 J strain, we performed a knockout study using single TAM-deficient mice. We treated platelets isolated from TAM knockout mice with the Glycoprotein VI (GPVI) agonists convulxin, poly(PHG), and collagen-related triple-helical peptide (CRP), as well as thrombin for in-vitro experiments. We used a laser-induced cremaster arterial injury model for thrombosis experiments in vivo. Deficiency of the tyrosine kinase receptors, Axl or Tyro3, but not Mertk, inhibited aggregation, spreading, JON/A binding, and P-selectin expression of platelets in vitro. In vivo, platelet thrombus formation was significantly decreased in Axl−/− and Tyro3−/− mice, but not in Mertk−/− mice. Upon stimulation with glycoprotein VI (GPVI) agonists, tyrosine phosphorylation of signaling molecules, including spleen tyrosine kinase (Syk) and phospholipase C-γ2 (PLCγ2), was decreased in Axl−/− and Tyro3−/− platelets, but not in Mertk−/− platelets. While platelet aggregation induced by agonists did not differ in the presence or absence of the Gas6 neutralizing antibody, the platelet aggregation was inhibited by anti-Axl or anti-Tyro3 neutralizing antibodies antibody, but not the anti-Mertk antibody. Additionally, the recombinant extracellular domain of Axl or Tyro3, but not that of Mertk, also inhibited platelet aggregation. These data suggest that Axl and Tyro3, but not Mertk, have an important role in platelet activation and thrombus formation, and mechanistically may do so by a pathway that regulates inside to outside signaling and heterotypic interactions via the extracellular domains of TAMs.
- 12 December 2018
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 16 (1) , 1-14
Open AccessTyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation
Previously, several studies have shown that Tyro3, Axl, and Mertk (TAM) receptors participate in platelet activation and thrombosis. However, the role of individual receptors is not fully understood. Using single receptor-deficient platelets from TAM knockout mice in the C57BL/6 J strain, we performed a knockout study using single TAM-deficient mice. We treated platelets isolated from TAM knockout mice with the Glycoprotein VI (GPVI) agonists convulxin, poly(PHG), and collagen-related triple-helical peptide (CRP), as well as thrombin for in-vitro experiments. We used a laser-induced cremaster arterial injury model for thrombosis experiments in vivo. Deficiency of the tyrosine kinase receptors, Axl or Tyro3, but not Mertk, inhibited aggregation, spreading, JON/A binding, and P-selectin expression of platelets in vitro. In vivo, platelet thrombus formation was significantly decreased in Axl−/− and Tyro3−/− mice, but not in Mertk−/− mice. Upon stimulation with glycoprotein VI (GPVI) agonists, tyrosine phosphorylation of signaling molecules, including spleen tyrosine kinase (Syk) and phospholipase C-γ2 (PLCγ2), was decreased in Axl−/− and Tyro3−/− platelets, but not in Mertk−/− platelets. While platelet aggregation induced by agonists did not differ in the presence or absence of the Gas6 neutralizing antibody, the platelet aggregation was inhibited by anti-Axl or anti-Tyro3 neutralizing antibodies antibody, but not the anti-Mertk antibody. Additionally, the recombinant extracellular domain of Axl or Tyro3, but not that of Mertk, also inhibited platelet aggregation. These data suggest that Axl and Tyro3, but not Mertk, have an important role in platelet activation and thrombus formation, and mechanistically may do so by a pathway that regulates inside to outside signaling and heterotypic interactions via the extracellular domains of TAMs.
- 1 August 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (suppl_1)
6182Does myocardial bridge assessed by coronary CT angiography predict vasospasm of left anterior descending?
Background: Myocardial bridge (MB) of the left anterior descending (LAD) identified as “milking effect” on invasive coronary angiography (ICA) has been reported to be associated with vasospastic angina.
- 1 August 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (suppl_1)
6182Does myocardial bridge assessed by coronary CT angiography predict vasospasm of left anterior descending?
Background: Myocardial bridge (MB) of the left anterior descending (LAD) identified as “milking effect” on invasive coronary angiography (ICA) has been reported to be associated with vasospastic angina.
- 19 December 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, ix16-ix30
104P Feasibility of dose-dense doxorubicin and cyclophosphamide (ddAC) followed by taxane (T) in Japanese women with early breast cancer: A retrospective study
Aim/Background: Since in Japan pegfilgrastim was approved as the first G-CSF indicated for prophylactic use in many cancers including breast cancer in September 2014, ddAC (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 on day 1 and pegfilgrastim 3.6 mg/body on day 2 every 2 weeks for 4 cycles) followed by T, one of the global standard regimens for early breast cancer, became available. The goal of this study is to examine the feasibility and efficacy of ddAC-T in Japanese women with early breast cancer.
- 19 December 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, ix16-ix30
104P Feasibility of dose-dense doxorubicin and cyclophosphamide (ddAC) followed by taxane (T) in Japanese women with early breast cancer: A retrospective study
Aim/Background: Since in Japan pegfilgrastim was approved as the first G-CSF indicated for prophylactic use in many cancers including breast cancer in September 2014, ddAC (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 on day 1 and pegfilgrastim 3.6 mg/body on day 2 every 2 weeks for 4 cycles) followed by T, one of the global standard regimens for early breast cancer, became available. The goal of this study is to examine the feasibility and efficacy of ddAC-T in Japanese women with early breast cancer.
- Open Access
- 25 September 2014
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 13 (1) , 150
Platelet-derived sphingosine 1-phosphate induces migration of Jurkat T cells
The migration of T cell to atherosclerotic lesions is proposed to be involved in the pathogenesis of the atherosclerosis. Sphingosine 1-phosphate (S1P), a bioactive lysophospholipid released from activated platelets, exerts a variety of responses such as cell migration and proliferation, and reportedly induces T cell migration. Accordingly, platelet-T cell interactions may exist based on T cell responses triggered by platelet-derived S1P. S1P was measured using two-step lipid extraction followed by high-performance liquid chromatography (HPLC) separation while other phospholipids were determined by an enzymatic assay. The expression of S1P and lysophosphatidic acid receptors on Jurkat T cells was examined by RT-PCR and flow cytometry. Jurkat cell migration by S1P and the supernatant of activated platelets (SAP) was evaluated by a modified Boyden’s chamber assay. S1P1 receptor was confirmed to be expressed on Jurkat T cell by RT-PCR and flow cytometry. S1P at 10-100 nM induced strong Jurkat cell migration, which was inhibited by the S1P1 (and S1P3) antagonist VPC23019 and the Gi inactivator pertussis toxin (PTX). We found that the supernatant (releasate) of human platelets activated by collagen stimulation, which contains S1P abundantly, induced Jurkat cell migration and that the migration was inhibited by VPC23019 and PTX. In addition, human serum, into which platelet contents (including S1P) are fully released, induced the Jurkat cell migration, which was also inhibited by VPC23019. Our findings suggest that platelet-derived S1P induces Jurkat T cell migration possibly via S1P1. S1P may be a key molecule involved in the responses triggered by platelet-T cell interactions, including atherosclerosis.
- 25 September 2014
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 13 (1) , 150
Open AccessPlatelet-derived sphingosine 1-phosphate induces migration of Jurkat T cells
The migration of T cell to atherosclerotic lesions is proposed to be involved in the pathogenesis of the atherosclerosis. Sphingosine 1-phosphate (S1P), a bioactive lysophospholipid released from activated platelets, exerts a variety of responses such as cell migration and proliferation, and reportedly induces T cell migration. Accordingly, platelet-T cell interactions may exist based on T cell responses triggered by platelet-derived S1P. S1P was measured using two-step lipid extraction followed by high-performance liquid chromatography (HPLC) separation while other phospholipids were determined by an enzymatic assay. The expression of S1P and lysophosphatidic acid receptors on Jurkat T cells was examined by RT-PCR and flow cytometry. Jurkat cell migration by S1P and the supernatant of activated platelets (SAP) was evaluated by a modified Boyden’s chamber assay. S1P1 receptor was confirmed to be expressed on Jurkat T cell by RT-PCR and flow cytometry. S1P at 10-100 nM induced strong Jurkat cell migration, which was inhibited by the S1P1 (and S1P3) antagonist VPC23019 and the Gi inactivator pertussis toxin (PTX). We found that the supernatant (releasate) of human platelets activated by collagen stimulation, which contains S1P abundantly, induced Jurkat cell migration and that the migration was inhibited by VPC23019 and PTX. In addition, human serum, into which platelet contents (including S1P) are fully released, induced the Jurkat cell migration, which was also inhibited by VPC23019. Our findings suggest that platelet-derived S1P induces Jurkat T cell migration possibly via S1P1. S1P may be a key molecule involved in the responses triggered by platelet-T cell interactions, including atherosclerosis.
- Open Access
- 12 November 2013
- Published by Springer Nature in Thrombosis Journal
- Vol. 11 (1) , 23
VacA, the vacuolating cytotoxin of Helicobacter pylori, binds to multimerin 1 on human platelets
Platelets were activated under the infection with H. pylori in human and mice. We investigated the role of VacA, an exotoxin released by H. pylori in this context. Acid-activated VacA, but not heated VacA, induced platelet CD62P expression. However, VacA reacted with none of the alleged VacA receptors present on platelet membranes. We therefore analyzed VacA associated proteins obtained through VacA affinity chromatography, using MALDI-TOF-MS. Multimerin1 was detected in two consecutive experiments, as the binding protein for VacA. Plasmon resonance confirmed their binding, and dot blot analysis revealed that the peptide sequence AA 321-340 of multimerin 1 is the binding site for VacA. In conclusion, we propose a new interaction between multimerin1 and VacA , which may give another insight into H. pylori-induced platelet activations under H. pylori infection.
- 12 November 2013
- Published by Springer Nature in Thrombosis Journal
- Vol. 11 (1) , 23
Open AccessVacA, the vacuolating cytotoxin of Helicobacter pylori, binds to multimerin 1 on human platelets
Platelets were activated under the infection with H. pylori in human and mice. We investigated the role of VacA, an exotoxin released by H. pylori in this context. Acid-activated VacA, but not heated VacA, induced platelet CD62P expression. However, VacA reacted with none of the alleged VacA receptors present on platelet membranes. We therefore analyzed VacA associated proteins obtained through VacA affinity chromatography, using MALDI-TOF-MS. Multimerin1 was detected in two consecutive experiments, as the binding protein for VacA. Plasmon resonance confirmed their binding, and dot blot analysis revealed that the peptide sequence AA 321-340 of multimerin 1 is the binding site for VacA. In conclusion, we propose a new interaction between multimerin1 and VacA , which may give another insight into H. pylori-induced platelet activations under H. pylori infection.
- 1 June 2013
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 11 (s1) , 330-339
Platelet receptors activated via mulitmerization: glycoprotein VI, GPIb‐IX‐V, and CLEC‐2
- 1 June 2013
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 11 (s1) , 330-339
Platelet receptors activated via mulitmerization: glycoprotein VI, GPIb‐IX‐V, and CLEC‐2
- 14 May 2013
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 20 (6) , 629-636
Aspirin Half Maximal Inhibitory Concentration Value on Platelet Cyclooxygenase1 in Severe Type-2 Diabetes Mellitus is not Significantly Different from that of Healthy Individuals
It is implicated that diabetic patients are more resistant to aspirin therapy than patients with other diseases or healthy individuals. We evaluated the inhibitory effects of aspirin on aggregation and the cyclooxygenase activity of platelets of 10 patients with severe type-2 diabetes mellitis (DM) and compared the results with those of healthy individuals. Although platelet aggregation had a tendency to be more resistant to aspirin with the DM group, there was no significant difference in half maximal inhibitory concentration 50 values of aspirin on the cyclooxygenase activity between the patients with DM and healthy individuals. Thus, the residual platelet aggregability uninhibited by aspirin appears to be independent of the cyclooxygenase activity. Since adenosine diphosphate (ADP) receptor blocking almost completely inhibited the residual platelet aggregability, it is suggested that hyperreactivity to ADP is more prevalent in patients with DM.
- 14 May 2013
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 20 (6) , 629-636
Aspirin Half Maximal Inhibitory Concentration Value on Platelet Cyclooxygenase1 in Severe Type-2 Diabetes Mellitus is not Significantly Different from that of Healthy Individuals
It is implicated that diabetic patients are more resistant to aspirin therapy than patients with other diseases or healthy individuals. We evaluated the inhibitory effects of aspirin on aggregation and the cyclooxygenase activity of platelets of 10 patients with severe type-2 diabetes mellitis (DM) and compared the results with those of healthy individuals. Although platelet aggregation had a tendency to be more resistant to aspirin with the DM group, there was no significant difference in half maximal inhibitory concentration 50 values of aspirin on the cyclooxygenase activity between the patients with DM and healthy individuals. Thus, the residual platelet aggregability uninhibited by aspirin appears to be independent of the cyclooxygenase activity. Since adenosine diphosphate (ADP) receptor blocking almost completely inhibited the residual platelet aggregability, it is suggested that hyperreactivity to ADP is more prevalent in patients with DM.
- 12 February 2012
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 18 (3) , 272-280
Causes of Thrombocytopenia in Chronic Hepatitis C Viral Infection
We retrospectively studied 89 patients with chronic hepatitis C virus (HCV) infection, including 50 chronic hepatitis (CH) cases, 18 liver cirrhosis (LC) cases, and 21 LC with hepatocellular carcinoma (LC + HCC) cases, with regard to various factors related with thrombocytopenia. The platelet count decreased with the stage advancement of liver diseases. Multiple regression analysis revealed that splenomegaly and von Willebrand factor (vWF) were explanatory variables that correlated with thrombocytopenia. Splenomegaly appears to be the most responsible factor, although there are a considerable number of thrombocytopenic cases without splenomegaly, suggesting other factors may also be responsible. The vWF level is inversely correlated with the platelet count. Soluble thrombomodulin, a marker of endothelial dysfunction, increases with the advancement of liver fibrosis. It is positively correlated with vWF and inversely with the platelet count. Our present results imply that vascular endothelial dysfunction is also involved in thrombocytopenia during chronic HCV infection.
- 12 February 2012
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 18 (3) , 272-280
Causes of Thrombocytopenia in Chronic Hepatitis C Viral Infection
We retrospectively studied 89 patients with chronic hepatitis C virus (HCV) infection, including 50 chronic hepatitis (CH) cases, 18 liver cirrhosis (LC) cases, and 21 LC with hepatocellular carcinoma (LC + HCC) cases, with regard to various factors related with thrombocytopenia. The platelet count decreased with the stage advancement of liver diseases. Multiple regression analysis revealed that splenomegaly and von Willebrand factor (vWF) were explanatory variables that correlated with thrombocytopenia. Splenomegaly appears to be the most responsible factor, although there are a considerable number of thrombocytopenic cases without splenomegaly, suggesting other factors may also be responsible. The vWF level is inversely correlated with the platelet count. Soluble thrombomodulin, a marker of endothelial dysfunction, increases with the advancement of liver fibrosis. It is positively correlated with vWF and inversely with the platelet count. Our present results imply that vascular endothelial dysfunction is also involved in thrombocytopenia during chronic HCV infection.
- 1 January 2012
- Vol. 60 (1) , 52-8
[Recent development in platelet functions: roles beyond thrombosis].
In addition to their roles in thrombosis and hemostasis, there is an increasing body of evidence to suggest that platelets have diverse functions in various biological reactions. Of these, synthesis of specific proteins in a timely manner, involvement in inflammation, roles in anti-bacteria and anti-parasite protection, and supportive roles in liver regeneration have attracted the attention of a number of scientists. We have recently found a novel platelet-activating receptor, CLEC-2, which reacts with a snake venom, Rhodocytin. CLEC-2 has an intracellular signal transduction pathway quite similar to that of GOVI, except for its hemi-Y-xx-L motif. The endogenous ligand for CLEC-2 was identified by us as podoplanin, which is present in renal podocytes, lung alveolar macrophages, and lymphatic endothelial cells, and some types of malignant tumors. We found that CLEC-2/podoplanin interaction plays an important role in the metastasis of tumor cells with podoplanin expression. We have also found that hemophilic interaction between CLEC-2 molecules contributes to thrombus formation in vivo. CLEC-2 interaction with podoplan expressed on lymphatic endothelial cells appears to play an important role in the separation between veins and lymphatic vessels during the stage of fetal development.
- 1 January 2012
- Vol. 60 (1) , 52-8
[Recent development in platelet functions: roles beyond thrombosis].
In addition to their roles in thrombosis and hemostasis, there is an increasing body of evidence to suggest that platelets have diverse functions in various biological reactions. Of these, synthesis of specific proteins in a timely manner, involvement in inflammation, roles in anti-bacteria and anti-parasite protection, and supportive roles in liver regeneration have attracted the attention of a number of scientists. We have recently found a novel platelet-activating receptor, CLEC-2, which reacts with a snake venom, Rhodocytin. CLEC-2 has an intracellular signal transduction pathway quite similar to that of GOVI, except for its hemi-Y-xx-L motif. The endogenous ligand for CLEC-2 was identified by us as podoplanin, which is present in renal podocytes, lung alveolar macrophages, and lymphatic endothelial cells, and some types of malignant tumors. We found that CLEC-2/podoplanin interaction plays an important role in the metastasis of tumor cells with podoplanin expression. We have also found that hemophilic interaction between CLEC-2 molecules contributes to thrombus formation in vivo. CLEC-2 interaction with podoplan expressed on lymphatic endothelial cells appears to play an important role in the separation between veins and lymphatic vessels during the stage of fetal development.
- Open Access
- 1 January 2012
- Published by Springer Nature in Thrombosis Journal
- Vol. 10 (1) , 8
A time of change at Thrombosis Journal
Thrombosis and hemostasis related disease have a heavy burden in cardiovascular disease and it is important to have a journal where research into this can be accessed by all.
- 1 January 2012
- Published by Springer Nature in Thrombosis Journal
- Vol. 10 (1) , 8
Open AccessA time of change at Thrombosis Journal
Thrombosis and hemostasis related disease have a heavy burden in cardiovascular disease and it is important to have a journal where research into this can be accessed by all.